February 2026

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

Pengana Global Private Credit Trust reported a robust half-year performance with $7.5 million net profit and a stable NAV of $2.00 per unit, supported by a $69 million capital raise and an 8.9% annual yield. Despite increased market volatility, the Trust’s diversified private credit portfolio remains resilient.

KKR Credit Income Fund reported a $7.1 million operating profit for the half-year ending December 2025, down sharply from last year, while reinstating its Distribution Reinvestment Plan and maintaining steady monthly distributions.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Pengana Private Equity Trust reported a significant decline in half-year profit for the period ending 31 December 2025, yet increased its interim distribution to unitholders. The Trust’s net asset value per unit showed a modest rise despite challenging market conditions.

Globe International reported a 3.1% revenue increase to $98.2 million for the half-year ended December 2025, despite a 27% drop in EBIT due to unexpected US tariffs. The company maintains its interim dividend, signalling steady shareholder returns amid geopolitical challenges.

StepChange Holdings Limited reports a strong half-year performance post-IPO, with $24.36 million in revenue and a net profit of $524,400, underpinned by key acquisitions and US expansion.

Desane Group Holdings reports a modest half-year profit with stable assets and gearing, completes a key property sale, and pushes forward with a major industrial development in Penrith.

Bapcor Limited reported a statutory loss of $104.8 million for the first half of FY26 and announced a fully underwritten $200 million equity raising to strengthen its balance sheet and support operational recovery.

TZ Limited reported a $1.92 million loss for the half-year ending December 2025, with revenues of $5.4 million impacted by delayed US projects and integration challenges from its Keyvision acquisition. The company is banking on large tenders and expanding Microsoft data centre sales to drive recovery.

Rincon Resources has uncovered a significantly larger gold-copper mineralised zone at its Telfer South project, extending the known strike to over 1km with exceptional historic grades. This discovery sets the stage for a major drilling campaign aimed at expanding the resource base.

NTAW Holdings reported a reduced half-year loss of $9.7 million on a 12.3% revenue decline, driven by operational challenges and brand distribution changes. The company is focusing on cost restructuring and strategic partnerships to restore growth.

Metrics Real Estate Multi-Strategy Fund has reported a striking increase in half-year profit and distributions, underpinned by strong commercial real estate investments across debt and equity portfolios.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Cettire Limited reported a 2.8% revenue decline to $382.8 million and a net loss of $1.05 million for the half-year ended 31 December 2025, impacted by softer US demand and rising costs. Despite these headwinds, the company maintains a strong cash position and is focused on profitable growth.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

WAM Active Limited reported a record half-year profit with its investment portfolio soaring 31.4%, significantly outperforming benchmarks. The company also declared increased fully franked dividends and completed a $70.7 million capital raise, boosting assets under management beyond $151 million.

Bapcor Limited reported a statutory loss of $104.8 million for the first half of FY26, alongside an underlying profit in line with guidance. The company announced a $200 million equity raising to strengthen its balance sheet and fund a strategic turnaround.

RPM Automotive Group Limited has reported a challenging first half of FY2026, with revenue down 11% and a net loss of $1.62 million. The company cites macroeconomic pressures and slower progress on new initiatives as key factors.

Neurizon Therapeutics has commenced dosing in a major Phase 2/3 trial of its lead drug NUZ-001 for ALS, marking a critical step in advancing treatment options for this devastating disease.

Qoria Limited reported a 25% revenue increase to nearly $69 million for H1 FY2026 but also a widening net loss of $24.5 million. The company announced a transformative merger with US-based Aura to create a global digital safety leader.

Lynas Rare Earths Ltd has reported a striking half-year turnaround with a 1260% surge in net profit, underpinned by rising rare earth prices and strategic expansions. The company also completed a major equity raise to fuel its ambitious Towards 2030 growth plan.

Aurelia Metals Limited reported a robust half-year result for December 2025, with revenue climbing 27% and net profit after tax rising 26%, driven by production ramp-up at the Federation Mine and progress on the Great Cobar Project.